Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10723MR)

This product GTTS-WQ10723MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10723MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6226MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ10923MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MABT5102A
GTTS-WQ13052MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ7185MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ13772MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ13204MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ15960MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ5820MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ChAglyCD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW